drugset
Drugs / Autologous Hematopoietic Stem Cell Transplant
last change Mar 2022 re-read 3 minutes ago

Autologous Hematopoietic Stem Cell Transplant

Cell therapy

Developed for
disease related to solid organ transplantation · rheumatoid arthritis
Investigated by
Gary A Levy, O. Ont. MD. FRCP AGAF · Ottawa Hospital Research Institute · Richard Burt, MD

Trials 2

today NCT02549586 · Ph 2 NCT00278551 · Ph 1
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00278551 Jun 1997 → Nov 2011 rheumatoid arthritis Richard Burt, MD Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT02549586 Dec 2015 → Apr 2020 disease related to solid organ transplantation Gary A Levy, O. Ont. MD. FRCP AGAF Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Autologous Hematopoietic Stem Cell Transplant “Autologous Hematopoietic Stem Cell Transplant” NCT00278551 ↗
1

NCT02549586 ↗
Modality Cell therapy “Autologous hematopoietic stem cell transplantation (aHSCT) could be used to stop progression of recurrent PSC and promote operational tolerance.” PMID 34049362 ↗ Mar 2022